Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. - Wikidata - awgldk - TriplyDB

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

http://www.wikidata.org/entity/Q38743961

about

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?Breast cancer treatment-induced cardiotoxicity.Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.Dual HER2 Blockade.Risk Factors and Preventions of Breast Cancer.The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review.Update Breast Cancer 2017 - Implementation of Novel Therapies.ASCO 2017: highlights in breast cancer.Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity.Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016.Immunotherapy of cancer: targeting cancer during active disease or during dormancy?Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety stu Male Breast Cancer: Pink Ribbon Blues.Kinase-targeted cancer therapies: progress, challenges and future directions.Mechanisms of receptor tyrosine kinase activation in cancer.Breast cancer in 2017: Spurring science, marking progress, and influencing history.Advances in the management of HER2-positive early breast cancer.International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.A Convergence-Based Framework for Cancer Drug Resistance.Major clinical research advances in gynecologic cancer in 2017.Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor.Activating HER2 mutations as emerging targets in multiple solid cancers.Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia.The Conundrum of Adjuvant HER2 Treatment Options.Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.Should age impact breast cancer management in young women? Fine tuning of treatment guidelines.Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.ABC4 Consensus: Assessment by a German Group of Experts Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results Overview of Breast Cancer Therapy Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

P2860

Q33921813-20227224-0544-40AE-AA6E-5A9E766FCE61 Q39428826-271346C4-36A4-4731-B69E-853658441A12 Q41012013-82C7A80F-A8A7-4DF2-948F-566B5A2109FD Q41661268-32C7DBE6-BE5E-4C56-8584-609C37DDCE27 Q42373758-ADE8E094-942D-4B35-86E4-6564641176F9 Q46222280-F731D011-30D2-4317-8DA7-7B8DB8A1EACE Q47100005-FA120EFD-6671-44DA-B683-3D014E34BFF9 Q47109695-28FB1F3E-03ED-4062-A028-C2211C4025F6 Q47110841-5E9C202F-AC94-45C7-B3C7-91E20824F844 Q47114225-637AF73A-F81A-43EB-AA83-66C9AA8E1311 Q47138534-BCE4E103-A0C1-4F40-AB6E-C425E65035BD Q47286758-77EBA731-A94E-45BF-A432-4503321A394F Q47368780-68CC1F01-FCAC-4165-9C86-E10E799A0F27 Q47372732-6B1DA380-50A5-47D6-8587-EAFB1DAE1B7E Q47729557-7445E2DD-C256-4F08-9760-E2F7E77C8463 Q47795804-E7FBDEF1-C9E8-43D1-8E93-83893CFAA280 Q48102534-BF40EBD7-37B6-4F07-B6BC-7C739848E1A8 Q48354684-7518E0F4-3466-42A1-B7CA-4455D5F8D50D Q49668714-EBDE8F59-6040-432F-92C8-74AD063BAA04 Q49813617-3553D16C-480F-4D0B-9DA8-3469F9630E0A Q49887882-360665E0-C2CC-47F4-9206-067D49621F6F Q49888000-B5BDD6D0-6C93-4B0C-9A59-180A0DDEBA65 Q49907753-45F7DF79-93B5-4A34-963B-871FDFCCA074 Q50084900-544C545B-C72A-4890-884F-055E50D84B39 Q52714397-4FE8B06F-4F90-46D6-9C77-87859932FC9B Q52780137-D99C9E7C-254A-4AD8-9CB6-422C0F97B41F Q53682041-8A1CB2F6-1BF2-4603-9357-B075C4EB4E42 Q54952356-74A323E2-3BC8-4094-8355-D5A8DDCB7BAA Q54976456-3035A52D-06D3-4C36-A44F-EC058F2E7B59 Q54986604-36605003-4662-4E86-8FB9-F1E2022AF6C9 Q55018821-CC238BF4-74A9-4192-B5D6-B517F1A520B9 Q55216913-433D3AD2-29EC-4E2C-8C0A-A4AEA8D63C98 Q55261407-A79AC6E0-C1B6-4BC6-AB85-C688913ABE92 Q55346396-32781018-901D-4D42-A662-FCB474B63EB3 Q55431604-5B8A62FB-D75D-42F3-8BD2-F47A92AA6B3B Q55466488-F3E0EDB7-4B7B-42D1-8586-F9FAA5F5D929 Q56968314-2ED9E230-6A73-4700-8F55-9D1738F980D6 Q57108099-3FC36B61-304F-47E4-BFEB-432226F26368 Q57110718-025D44EB-F203-4E79-B08F-0A1126C8E782 Q57111046-A11F446F-F870-4EC9-8CA7-3008C559D9BB

P2860

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

http://www.wikidata.org/entity/Q38743961

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

@en

type

label

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

@en

prefLabel

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

@en

P1433

Q38743961-ACD23EEE-C984-42FD-9E03-FE1BC1B398FF

P1476

Q38743961-7F6200D8-6DB6-4957-A2EA-8D0BD9DE64E3

P2093

Q38743961-0061B290-C7B5-4E93-AB6C-C93DD28DE6F8

Q38743961-04EAB6E9-93FA-4CDF-83BA-5BB5FA21B919

Q38743961-0E0AFE82-E362-48E3-AF2D-E8D572DCB119

Q38743961-18847E71-FDEE-4F7B-AB8D-7111CEACAA02

Q38743961-19742A9C-8986-46BD-8968-218921B12ECE

Q38743961-3B6CC2ED-D9E8-4082-8512-32CDF01B23FB

Q38743961-6F9A4ADE-BC30-4319-8A59-B602D0A60914

Q38743961-8A4118BE-FCC2-4309-9601-D095A9604F10

Q38743961-8FA2E507-D861-4528-8F2A-55BFDB3E69DA

Q38743961-982B77C1-EF76-40B7-B7D8-9765A087C509

P2860

Q38743961-14CD3F18-B410-4351-8726-098D61EEEFA5

Q38743961-1B580E3D-47BB-44E2-9EC6-35FE4623F910

Q38743961-2F8EA527-40C1-4FA8-909D-A574F89ACBFE

Q38743961-5BE04F7C-015C-4A63-86F5-3A9D403ED88D

Q38743961-79F84BA2-6AF3-4A92-8C54-C2E8645F4A59

Q38743961-8CF1DC6A-424F-4973-B645-EC6A8F47EB2D

Q38743961-8E814867-CFA4-440F-9452-9AB2B6C71B40

Q38743961-9E9731B9-6D79-4250-BCFA-1EA9F3343D97

Q38743961-D11D6DAD-8F0E-4067-8B45-C7ED454E41AD

Q38743961-DDED386C-14CD-4AE4-8BF5-7C8D3E910684

P304

Q38743961-292EEB50-DAF9-41F0-812B-9F862B3FC941

P31

Q38743961-B51211B7-03EF-456A-8171-95692D04A293

P356

Q38743961-672D53DA-8E62-4B12-8C83-0DF2DC62F0FA

P407

Q38743961-63136912-D52A-43D7-BC24-7E75BB1A2BBE

P433

Q38743961-3433E8F6-0CE9-40FE-9B06-87B1B06DBD43

P478

Q38743961-D2F5C68B-CC60-4111-A8E6-D6DF1881B968

P50

Q38743961-2299953C-E0CA-4B61-8F66-33E89DDD24DC

Q38743961-41AB6080-A307-4125-BE16-A4772E12199A

Q38743961-42C8C9E5-1506-4035-BA6C-FB6B7F764C5D

Q38743961-B6B67AD5-4E0F-45AD-A6A5-FBCC50D1E44F

P577

Q38743961-7DF474CE-91AE-4132-8845-ED2D75D42985

P698

Q38743961-A6531815-CD60-4ADB-ADDC-5AA7DFC2C0B3

P932

Q38743961-800F9159-04A1-4C84-B9A7-67898FE7923E

P356

P1433

The New England Journal of Medicine

P1476

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

@en

P2093

APHINITY Steering Committee and Investigators

http://www.w3.org/2001/XMLSchema#string

Adam Knott

http://www.w3.org/2001/XMLSchema#string

Amal Arahmani

http://www.w3.org/2001/XMLSchema#string

Denise A Yardley

http://www.w3.org/2001/XMLSchema#string

Dimitrios Zardavas

http://www.w3.org/2001/XMLSchema#string

Emma Clark

http://www.w3.org/2001/XMLSchema#string

Gunter von Minckwitz

http://www.w3.org/2001/XMLSchema#string

Istvan Lang

http://www.w3.org/2001/XMLSchema#string

Jose Bines

http://www.w3.org/2001/XMLSchema#string

Marion Procter

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Translating neoadjuvant therapy into survival benefits: one size does not fit all.

Adjuvant trastuzumab in HER2-positive breast cancer.

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

P304

122-131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1703643

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

377

http://www.w3.org/2001/XMLSchema#string

P50

Evandro de Azambuja

Christelle Levy

P577

2017-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28581356

http://www.w3.org/2001/XMLSchema#string

P932

5538020

http://www.w3.org/2001/XMLSchema#string